Getting Patents on Track at NIH

Image: Erica P. Johnson The National Institutes of Health has launched a new tracking system to streamline the licensing of discoveries. Officials hope the new system will improve the technology transfer process, allowing promising biomedical discoveries to be commercialized and brought to the public benefit more quickly. In October, the NIH activated TechTracS, a system to monitor technology transfers from intramural research programs. TechTracS uses computer database tools to help NIH offic

Written byTed Agres
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The National Institutes of Health has launched a new tracking system to streamline the licensing of discoveries. Officials hope the new system will improve the technology transfer process, allowing promising biomedical discoveries to be commercialized and brought to the public benefit more quickly.

In October, the NIH activated TechTracS, a system to monitor technology transfers from intramural research programs. TechTracS uses computer database tools to help NIH officials keep up-to-date on their patenting and licensing activities. The NIH collected $46 million (US) in licensing revenue in fiscal 2001 from intramural and extramural research, an amount that pales in comparison with the whopping $17.9 billion it obligated in fiscal 2001. The system is designed to better manage those resources. "We added about 1,000 different business rules, things that a patent attorney might go through," says Gary Barbarash, special assistant to the director of NIH's Office of Technology Transfer (OTT).

TechTracS was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies